Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Condition(s):Advanced Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer; Lung NeoplasmsLast Updated:July 31, 2017Withdrawn
Hide Studies Not Open or Pending
Condition(s):Advanced Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer; Lung NeoplasmsLast Updated:July 31, 2017Withdrawn
Condition(s):Diffuse Large B Cell LymphomaLast Updated:June 22, 2023Active, not recruiting
Condition(s):Advanced Cutaneous Squamous Cell CarcinomaLast Updated:February 12, 2020Unknown status
Condition(s):Carcinoma, Renal CellLast Updated:December 6, 2021Completed
Condition(s):Bladder CancerLast Updated:November 8, 2022Completed
Condition(s):Esophageal CancerLast Updated:March 12, 2024Recruiting
Condition(s):Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell LungLast Updated:January 17, 2024Completed
Condition(s):NeuroblastomaLast Updated:August 2, 2023Recruiting
Condition(s):B Cell LymphomaLast Updated:May 26, 2022Recruiting
Condition(s):Renal Cell Cancer Metastatic; Non-small Cell Lung Cancer Metastatic; Pleural Effusion, MalignantLast Updated:March 8, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.